WTA Mandates 1-Time SRY Gene Tests for All Players by 2026
Updated
Updated · bbc.co.uk · Jul 20
WTA Mandates 1-Time SRY Gene Tests for All Players by 2026
3 articles · Updated · bbc.co.uk · Jul 20
Summary
A new WTA eligibility policy taking effect Tuesday will require every player to provide a cheek swab, blood or saliva sample for a one-time SRY gene test to compete on the women's tour.
Only a negative result showing no SRY gene presence will clear a player to compete; a positive result triggers further medical assessment, and refusing testing can bring disciplinary action.
The rule replaces the WTA's 2024 standard, which allowed transgender women to play if testosterone stayed below 2.5 nmol/L for the previous two years; the tour says no transgender women are currently competing.
The WTA said the shift is meant to protect fair competition based on biological sex, aligning tennis with moves already adopted by World Athletics in 2025 and World Boxing.
The gene's discoverer calls SRY testing invalid. Why are sports bodies mandating it for female athletes?
What happens to the careers of intersex athletes who fail a genetic test not designed for them?
The WTA’s 2026 SRY Gene Policy: How Genetic Sex Testing Is Reshaping Eligibility in Women’s Tennis and Global Sports
Overview
The WTA has begun implementing its new eligibility policy, starting with player screening this year and moving towards full enforcement by July 2026. Recognizing the sensitivity and complexity of the issue, the WTA is committed to a dignified and thoughtful approach, ensuring all players are treated with respect. To support this transition, robust measures are in place to protect player information, including strict confidentiality and data privacy safeguards. Alongside the screening, a comprehensive player engagement program is running to educate and support athletes as they adapt to the new requirements, highlighting the WTA’s focus on both fairness and player well-being.